![conference banner](/images/conference-banner.jpeg)
摘要
近年来癌症治疗领域的巨大进步之一是免疫治疗的出现。免疫疗法,尤其是免疫检查点抑制剂,已经在实体瘤例如黑素瘤,乳腺癌和肺癌的临床前模型和临床试验中显示出有希望的结果。针对免疫微环境的治疗策略也已经应用于血液恶性肿瘤,如多发性骨髓瘤(MM),其特征是主要在骨髓(BM)中恶性浆细胞的克隆增殖的浆细胞瘤形成。 MM与细胞和体液免疫缺陷相关,表明疾病从前体状态的演变(未确定意义的单克隆丙种球蛋白(MGUS)和阴燃MM(sMM))与促进免疫逃逸和肿瘤的免疫抑制环境相关联生长。尽管治疗有显着进展,但MM主要是不治之症。因此,开发不仅靶向MM克隆本身而且针对MM免疫微环境的新型治疗剂是至关重要的。然而,BM微环境的复杂性和肿瘤细胞克隆的异质性使得开发MM的适当免疫治疗成为一项艰巨的任务。在本文中,我们回顾了疾病进展期间恶性浆细胞与骨髓免疫微环境之间相互作用的现有知识
关键词: 多发性骨髓瘤,脊髓,MDSC,效应T细胞,NK细胞,DCs,巨噬细胞检查点抑制剂。
Current Cancer Drug Targets
Title:Multiple Myeloma and the Immune Microenvironment
Volume: 17 Issue: 9
关键词: 多发性骨髓瘤,脊髓,MDSC,效应T细胞,NK细胞,DCs,巨噬细胞检查点抑制剂。
摘要: One of the great advances in the field of cancer therapy in recent years is the emergence of immune therapies. Immune therapies, especially immune checkpoint inhibitors, have shown promising results in pre-clinical models and clinical trials of solid tumors, such as melanoma, breast cancer and lung cancer. Therapeutic strategies targeting the immune microenvironment have also been applied to hematological malignancies such as multiple myeloma (MM), a plasma cell neoplasia characterized by clonal proliferation of malignant plasma cells mainly in the bone marrow (BM). MM is associated with both cellular and humoral immune deficiencies, indicating that the evolution of the disease from a precursor state (monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (sMM)) is associated with an immunosuppressive milieu that fosters immune escape and tumor growth. Despite significant advances in treatment, MM is mostly an incurable disease. Therefore, it is vital to develop novel therapeutic agents that not only target the MM clone itself but also the MM immune microenvironment. However, the complexity of the BM microenvironment and heterogeneity of tumor cell clones make it a difficult task for developing appropriate immune therapies of MM. In this article, we review the current knowledge of the interaction between malignant plasma cells and the bone marrow immune microenvironment during disease progression.
Export Options
About this article
Cite this article as:
Multiple Myeloma and the Immune Microenvironment, Current Cancer Drug Targets 2017; 17 (9) . https://dx.doi.org/10.2174/1568009617666170214102301
DOI https://dx.doi.org/10.2174/1568009617666170214102301 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diagnosis of Pathogens Using DNA Microarray
Recent Patents on Biotechnology Prodrug Design of Phenolic Drugs
Current Pharmaceutical Design Recent Patents on Nanoparticles and Nanoformulations for Cancer Therapy
Recent Patents on Drug Delivery & Formulation Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer
Current Drug Targets Extra-telomeric Functions of Human Telomerase: Cancer, Mitochondria and Oxidative Stress
Current Pharmaceutical Design Plumbagin: A Potential Anti-cancer Compound
Mini-Reviews in Medicinal Chemistry Recent Patents in Cell-Based Strategies for Soft Tissue Engineering in Plastic and Reconstructive Surgery
Recent Patents on Biomedical Engineering (Discontinued) Simple C-2-Substituted Quinolines and their Anticancer Activity
Letters in Drug Design & Discovery MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry An Overview of Targeting Legumain for Inhibiting Cancers
Current Pharmaceutical Design Recent Advances in the Development of Selective Small Molecule Inhibitors for Cyclin-Dependent Kinases
Current Topics in Medicinal Chemistry Design, Synthesis and Mode of Action of Some New 2-(4'-aminophenyl) benzothiazole Derivatives as Potent Antimicrobial Agents
Letters in Drug Design & Discovery Transient Expression of Recombinant sPDGFRα-Fc in CHO DG44 Cells using 50-mL Orbitally Shaking Disposable Bioreactors
Protein & Peptide Letters Serum miR-372 is a Diagnostic and Prognostic Biomarker in Patients with Early Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Editorial [ Hot Topic: Targeting Tumor Angiogenesis: An Update (Guest Editor: Girolamo Ranieri)]
Current Medicinal Chemistry Use of the Semiconductor Nanotechnologies “Quantum Dots” for in vivo Cancer Imaging
Recent Patents on Anti-Cancer Drug Discovery The Role of Diet Related Short-Chain Fatty Acids in Colorectal Cancer Metabolism and Survival: Prevention and Therapeutic Implications
Current Medicinal Chemistry Editorial [Hot Topic: The Impact of Microbiota and Cytokines on Inflammatory Bowel Disease (Executive Editors: Osamu Kanauchi and Keiichi Mitsuyama)]
Current Pharmaceutical Design Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Strategies for Increasing the Solubility and Bioavailability of Anticancer Compounds: β-Lapachone and Other Naphthoquinones
Current Pharmaceutical Design